MED12
MED12 (Mediator of RNA polymerase II transcription subunit 12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Cervical cancer, Endometrial cancer and 5 more.
Overview
Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors.
Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.38, genetic association 0.19, somatic mutation 0.80). IntOGen calls it a driver in 14 cohorts (9 activating, 5 loss-of-function), covering Acute Lymphoblastic Leukaemia, Cervical Squamous Cell Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Glioblastoma Multiforme, Low-Grade Glioma, NOS, Neuroblastoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MED12 (Mediator of RNA polymerase II transcription subunit 12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Cervical cancer, Endometrial cancer and 5 more.
- 1 · What it is
MED12 (Mediator of RNA polymerase II transcription subunit 12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Cervical cancer, Endometrial cancer and 5 more.
- 2 · What goes wrong in cancer
Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes.
- 3 · How drugs use it
No product in this corpus aims at MED12 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:11957 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q93074 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000184634 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: skin cancer 0.52, leukaemia 0.51 (GraphQL API, CC0)); IntOGen MED12 (driver in 14 cohorts (Act 9, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors. This subunit may specifically regulate transcription of targets of the Wnt signalling pathway and SHH signalling pathway. Location: Nucleus (UniProt). Locus Xq13.1 (HGNC).
- Prostate cancer: IntOGen driver in 5 cohorts (PRAD, PROSTATE)
- Cervical cancer: IntOGen driver in 2 cohorts (CESC)
- Endometrial cancer: IntOGen driver in 1 cohort (UCEC)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Leukaemia: Open Targets association 0.51 with leukaemia (MONDO_0005059)
- Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 9 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"MED12" OR ABSTRACT:"MED12" OR TITLE:"mediator complex subunit 12" OR ABSTRACT:"mediator complex subunit 12" OR TITLE:"Mediator of RNA polymerase II transcription subunit 12" OR ABSTRACT:"Mediator of RNA polymerase II transcription subunit 12" OR TITLE:"CAGH45" OR ABSTRACT:"CAGH45" OR TITLE:"OPA1" OR ABSTRACT:"OPA1" OR TITLE:"TRAP230" OR ABSTRACT:"TRAP230") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MED12, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCNOT3
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), Acute lymphoblastic leukaemia.
- TargetZMYM2
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Prostate cancer.
- TargetBIRC3
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), Acute lymphoblastic leukaemia.
- TargetTAL1
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Prostate cancer.
- TargetPAX5
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetLEF1
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetRPL5
Shares Leukaemia (all types), Skin cancer (all types), Glioma & glioblastoma, IntOGen.